Presence of Wuchereria bancrofti microfilaremia despite 7 years of annual ivermectin monotherapy mass drug administration for onchocerciasis control: a study in north-west Ethiopia. (3rd October 2015)

• Record Type: Journal Article
• Authors: Endeshaw, Tekola; Taye, Aseged; Tadesse, Zerihun; Katabarwa, Moses N.; Shafi, Oumer; Seid, Tewodros; Richards, Frank O.
• Is Part Of: Pathogens and global health. Volume 109:Number 7(2015)
• Page Start: 344
• Page End: 351
• Publication Date: 2015-10-03
• Subjects: Lymphatic filariasis -- Onchocerciasis -- Annual MDA -- Ivermectin -- Elimination; Communicable diseases -- Periodicals; Public health -- International cooperation -- Periodicals; World health -- Periodicals; 362.1969
• DOI: Http://www.tandfonline.com/doi/10.1080/20477724.2015.1103501
• Languages: English
• ISSNs: 2047-7724

Abstract

Abstract : Background: There is considerable interest in determining whether mass drug administration (MDA) with ivermectin for onchocerciasis control will eliminate coendemic lymphatic filariasis (LF). The objective of this study was to determine the prevalence of LF microfilaremia in onchocerciasis endemic districts that had received 7 years of MDA with ivermectin. Method: Three villages with a 2010 LF circulating antigenaemia prevalence (determined in a mapping exercise using immunochromatography tests) ranging from 23 to 56% were surveyed for the presence of Wuchereria bancrofti microfilaria (mf) in 2012. These villages had been treated with ivermectin MDA for onchocerciasis with reported total population coverage of ≥65%. A total of 774 residents aged 2 years and above, of both genders, provided 60 μl nocturnal blood samples between 10 pm and 2 am. Standard thick smears were prepared and examined microscopically after Giemsa staining for the presence of W. bancrofti mf. Results: The mean mf prevalence was 4.7% (village range 1.1–11.0%). The mean mf density was 9.8 mf/60 μl (village range 9–13.1) among the positive individuals. Children in the 2–4-year-old and 5–9-year-old age groups were infected suggesting transmission occurred during the MDA period. A village level review of MDA treatment coverage records showed an average total population coverage of 66.4% over a 7-year period, but with a considerable range of annual coverage (43.0–89.9%). In addition, village level treatment coverage data were missing from the village with the highest mf prevalence (11%) for 2 of the 7 years. Conclusion: 7 years of annual mass treatment with ivermectin monotherapy for onchocerciasis did not interrupt LF transmission. In expanding the onchocerciasis ivermectin MDA programme to include LF, albendazole should be added and treatment coverage improved.